$1.82
0[0.00%]
At close: Apr 26
Palatin Techs
(AMEX:PTN)Latest News for Palatin Techs Stock (AMEX:PTN)
Palatin Techs Stock (AMEX: PTN)
Categories: All
Friday, April 12, 2024
Monday, April 08, 2024
- Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study DataVandana Singh - Apr 8, 2024, 10:02AM
- Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024Benzinga Newsdesk - Apr 8, 2024, 7:31AM
Wednesday, February 28, 2024
- Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Feb 28, 2024, 2:02PM
- HC Wainwright & Co. Maintains Buy on Palatin Techs, Adjusts Price Target To $17Benzinga Newsdesk - Feb 28, 2024, 1:16PM
- Palatin Technologies shares are trading lower after the company announced results for its PL9643 MELODY-1 Pivotal Phase 3 clinical trial in patients with dry eye disease did not meet co-primary sign endpoints and secondary sign endpoints.Benzinga Newsdesk - Feb 28, 2024, 12:49PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Feb 28, 2024, 12:31PM
- Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock PlummetsVandana Singh - Feb 28, 2024, 10:57AM
- Dow Dips 200 Points; TJX Posts Upbeat SalesAvi Kapoor - Feb 28, 2024, 10:12AM
- Palatin Technologies Shared Resumed TradeBenzinga Newsdesk - Feb 28, 2024, 9:44AM
- Palatin Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Down -40.8%Benzinga Newsdesk - Feb 28, 2024, 9:36AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Feb 28, 2024, 8:06AM
- Palatin Reports Results Of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial In Patients With Dry Eye Disease; On An Intent-To-Treat Analysis, Co-primary Sign Endpoint And Secondary Sign Endpoints Not MetBenzinga Newsdesk - Feb 28, 2024, 7:34AM
Thursday, February 15, 2024
- HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price TargetBenzinga Newsdesk - Feb 15, 2024, 12:39PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Feb 15, 2024, 12:31PM
- Palatin Techs Reported Wednesday Q2 2024 GAAP EPS $(0.56) Misses $(0.20) Estimate, Sales $2.03M Miss $6.30M EstimateBenzinga Newsdesk - Feb 15, 2024, 7:35AM
- Earnings Scheduled For February 15, 2024Benzinga Insights - Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Tuesday, January 30, 2024
Wednesday, January 03, 2024
Wednesday, December 27, 2023
Wednesday, December 20, 2023
Monday, December 18, 2023
Friday, December 15, 2023
Monday, December 04, 2023
Tuesday, November 14, 2023
Monday, November 13, 2023
Monday, October 23, 2023
Thursday, October 19, 2023
Wednesday, October 18, 2023
Friday, October 13, 2023
Thursday, September 28, 2023
- Palatin's Cash, Cash Equivalents And Marketable Securities Were Approximately $11.M Sufficient To Fund Currently Anticipated Operating Expenses Through Calendar Year 2023Benzinga Newsdesk - Sep 28, 2023, 7:34AM
- Palatin Techs Q4 EPS $(0.91) Misses $(0.56) Estimate, Sales $1.76M Beat $1.37M EstimateBenzinga Newsdesk - Sep 28, 2023, 7:33AM
- Earnings Scheduled For September 28, 2023Benzinga Insights - Sep 28, 2023, 6:59AM
Wednesday, September 27, 2023
Tuesday, September 19, 2023
Thursday, September 07, 2023
Thursday, August 10, 2023
Tuesday, August 08, 2023
Monday, August 07, 2023
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Aug 7, 2023, 1:30PM
- Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Aug 7, 2023, 1:28PM
- HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price TargetBenzinga Newsdesk - Aug 7, 2023, 12:28PM
- Palatin Announces Partnership To Make Vyleesi Available To Patients On UpScriptHealth's Telehealth PlatformBenzinga Newsdesk - Aug 7, 2023, 7:34AM